Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Genentech, Inc. v. Amgen Inc.
Case Number:
1:17-cv-00165
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
March 01, 2017
Genentech Biosimilar Suit Tossed After Just 2 Weeks
A Delaware federal judge on Wednesday wiped out Genentech's newly filed lawsuit accusing Amgen of improperly concealing information about a proposed biosimilar of cancer drug Avastin, finding that the complaint isn't allowed under a landmark Federal Circuit ruling.
-
February 16, 2017
Amgen Hiding Biosimilar Info, Genentech Suit Says
Amgen is hypocritically withholding information about its proposed biosimilar of cancer drug Avastin and thereby undercutting potential patent litigation, Genentech charged in a complaint filed Wednesday in Delaware federal court.